Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 17/20 | 0.62 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.62 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.62 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.62 |
| ▸ | PLA2G2F | Q9BZM2 | 1/20 | 0.53 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7196785 | 0.94 | PLA2G1B (0.67) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7193938 | 0.93 | PLA2G1B (0.62) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7190951 | 0.91 | PLA2G1B (0.59) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL27574640 | 0.91 | PLA2G1B (0.59) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7193717 | 0.89 | PLA2G1B (0.58) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7192247 | 0.88 | PLA2G1B (0.57) | PLA2G1BPLA2G2APLA2G2EPLA2G5 | |
| SCHEMBL7737348 | 0.88 | PLA2G2A (0.55) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7645755 | 0.88 | PLA2G2A (0.54) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7737359 | 0.87 | PLA2G2A (0.54) | PLA2G1BPLA2G2APLA2G2EPLA2G5PLA2G2F | |
| SCHEMBL7186945 | 0.87 | PLA2G1B (0.67) | PLA2G1BPLA2G2APLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | claimed |
| US-6407104-B1 | Pyrrolo[1,2-a]pyrazine spla2 inhibitor | SHIONOGI & CO., LTD. (JP) | 2002-06-18 | — | — | US | claimed |
| WO-2001066111-A1 | COMPOSITIONS CONTAINING POTENTIAL SPLA2 INHIBITORS FOR THE TREATMENT OF PAIN | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| EP-1066290-A1 | PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2001-01-10 | — | — | EP | claimed |
| WO-1999051605-A1 | PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 1999-10-14 | — | — | WO | claimed |
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | CONCORD (HK) INTERNATIONAL EDUCATION LIMITED (HK) | 2003-05-08 | — | — | US | disclosed |
| EP-1265607-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA 2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6407104-B1 | Pyrrolo[1,2-a]pyrazine spla2 inhibitor | SHIONOGI & CO., LTD. (JP) | 2002-06-18 | — | — | US | disclosed |
| WO-2001066110-A2 | METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-09-13 | — | — | WO | disclosed |
| WO-2001055108-A2 | USE OF SPL A2 INHIBITORS FOR THE TREATMENT OF INFLAMMATION | ELI LILLY AND COMPANY (US) | 2001-08-02 | — | — | WO | disclosed |
| EP-1066290-A1 | PYRROLO[1,2-a]PYRAZINE sPLA 2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051605-A1 | PYRROLO[1,2-a]PYRAZINE sPLA2 INHIBITOR | SHIONOGI & CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087944-A1 | Method for the treatment of renal dysfunction with spla2 inhibitors | IDO2, SPINT2, IDO1 | PLA2G1B 26/4885PLA2G2A 63/4885PLA2G2E 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.